Chordia Therapeutics Past Earnings Performance
Past criteria checks 0/6
Chordia Therapeutics's earnings have been declining at an average annual rate of -918.1%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-918.1%
Earnings growth rate
-886.2%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -100.0% |
| Return on equity | -43.9% |
| Net Margin | n/a |
| Next Earnings Update | 14 Jan 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Chordia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 0 | -1,827 | 302 | 1,500 |
| 31 Aug 23 | 2,500 | 223 | 291 | 1,997 |
Quality Earnings: 190A is currently unprofitable.
Growing Profit Margin: 190A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 190A's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 190A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 190A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 190A has a negative Return on Equity (-43.91%), as it is currently unprofitable.